Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo

Annals of Hematology

Volumn 94, Issue 11, 2015, Pages 1907-1919

  Blank, Gregor ^a   Welker, Christian ^a   Sipos, Bence ^a   Sonntag, Katja ^a   Müller, Friederike ^a   Eckert, Franziska ^a   Seitz, Christian ^a   Nadalin, Silvio ^a   LaCorcia, Gina ^b   Königsrainer, Alfred ^a   Snell, Daniel ^b   Handgretinger, Rupert ^a   Schilbach, Karin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b SANOFI   (France)

Author keywords

Antibody therapy; Prevention of GVHD; Stem cell transplantation; T cell depletion; T cells

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GZ ALPHABETATCR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DRUG POTENCY; GAMMA DELTA T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HOST CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MORBIDITY; MORTALITY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; ADVERSE EFFECTS; ANIMAL; CELL CULTURE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; NONOBESE DIABETIC MOUSE; PROCEDURES; SURVIVAL; TRANSGENIC MOUSE; VACCINATION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELLS, CULTURED; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; VACCINATION;

EID: 84941996549     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2471-3     Document Type: Article

References (50)

1. Ferrara JL, Deeg HJ (1991) Graft-versus-host disease. N Engl J Med 324:667–674
2. Ferrara JLM, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373:1550–1561
3. Goker H, Haznedaroglu IC, Chao NJ (2001) Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29:259–277
4. Korngold R, Sprent J (1978) Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T-cells from marrow. J Exp Med 148:1687–1698
5. Chiang EY, Kolumam G, McCutcheon KM, Young J, Lin Z, Balazs M, Grogan JL (2012) In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-disease. PLoS One 7(3), e33106
6. Paczesny S, Hanauer D, Reddy P (2012) New perspectives on the biology of acute GVHD. Bone Marrow Transplant 45:1–11
7. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M (2004) A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 34:621–625
8. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH (2004) Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10:328–336
9. Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Rischewski J, Sonnenberg S, Ayuk F, Tögel F, Schade U, Fiegel H, Erttmann R, Löliger C, Zander AR (2002) In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 29:683–689
10. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Sacchi N, van Lint MT, Bosi A, Gruppo Italiano Trapianti Midollo Osseo (GITMO) (2006) Thymoglobulin prevents chronic graft-versus- host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12:560–565
11. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S, Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100:3121–3127
12. + αβT cells by the novel humanized antibody GZ-αβTCR targeting human αβTCR. Bone Marrow Transplant 50(3):390–401
13. King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J, Laning J, Fodor W, Foreman O, Burzenski L, Chase TH, Gott B, Rossini AA, Bortell R, Shultz LD, Greiner DL (2009) Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 157:104–118
14. Ito R, Katano I, Kawai K, Hirata H, Ogura T, Kamisako T, Eto T, Ito M (2009) Highly sensitive model for xenogeneic GVHD using severe immunodeficient NOG mice. Transplantation 87(11):1654–1658
15. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, Ferrara JL (1996) An experimental model of ideopathic pneumonia syndrome after bone marrow transplantation: I. The role of minor antigens and endotoxin. Blood 88:3230–3239
16. Gregoire-Gauthier J, Durrieu L, Duval A, Fontaine F, Dieng MM, Bourgey M, Patey-Mariaud de Serre N, Louis I, Haddad E (2012) Use of immunoglobulins in the prevention of GVHD in a xenogeneic NOD/SCID/γc- mouse model. Bone Marrow Transplant 47:439–450
17. Wilson J, Cullup H, Lourie R, Sheng Y, Palkova A, Radford KJ, Dickinson AM, Rice AM, Hart DN, Munster DJ (2009) Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med 206:387–398
18. Pidala J (2011) Graft-versus-host disease following allogeneic hematopoietic cell transplantation. Cancer Control 18(4):268–276
19. Paczesny S, Choi SW, Ferrara JLM (2009) Acute graft-versus-host disease: new treatment strategies. Curr Opin Hematol 16:427–436
20. Sandhu JS, Gorczynski R, Shpitz B, Gallinger S, Nguyen HP, Hozumi N (1995) A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. Transplantation 60:179–184
21. Ware CF (2005) Network communications: lymphotoxins, LIGHT and TNF. Annu Rev Immunol 23:787–819
22. Piñana JL, Valcárcel D, Martino R, Moreno ME, Sureda A, Briones J, Brunet S, Sierra J (2006) Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 12(11):1135–1141
23. Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KR, McCune JS, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, Anasetti C (2005) A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 11(6):465–471
24. Funke VA, de Medeiros CR, Setúbal DC, Ruiz J, Bitencourt MA, Bonfim CM, Neto JZ, Pasquini R (2006) Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 37(10):961–965
25. Carella AM, Beltrami G, Scalzulli PR, Carella AM Jr, Corsetti MT (2004) Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 33(1):131–132
26. Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A, Ciceri F, Milone G, Cesaro S, Bandini G, Dini G, Corradini P, Fanin R (2004) Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 89(11):1352–1359
27. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, Rifkin RM, Abhyankar S, Briggs AD, Burt R, Lipani J, Roskos LK, White JM, Havrilla N, Schwab G, Heslop HE (2001) Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 98:2052–2058
28. Shapira MY, Resnick IB, Dray L, Aker M, Stepensky P, Elad S, Gesundeheidt B, Samuel S, Or R (2009) A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. Cytotherapy 11(1):61–67
29. Karapinar DY, Karadaş N, Ay Y, Akin M, Balkan C, Aydinok Y, Kavakli K (2014) Rabbit antithymocyte globulin treatment in childhood acquired severe aplastic anemia. Pediatr Hematol Oncol 31(1):20–28
30. Golfieri R, Giampalma E, Lalli A, Sama C, Venturoli N, Mazziotti A, Gozzetti G, Gavelli G (1994) Pulmonary complications from monoclonal antibody (OKT3) immunosuppression in patients who have undergone an orthotopic liver transplant. Radiol Med 87(1–2):58–64
31. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O’Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99(12):4357–4363
32. Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE, Moss PA, Milligan DW (2002) Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100(5):1619–1627
33. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS (2003) CD4 + CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9:1144–1150
34. MacMillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR (2007) A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 109:2657–2662
35. Blazar BR, Taylor PA, Vallera DA (1994) In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice. J Immunol 152(7):3665–3675
36. Hirsch R, Archibald J, Gress RE (1991) Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab’)2 fragments of anti-CD3 monoclonal antibody. F(ab’)2 fragments induce a selective T helper dysfunction. J Immunol 147(7):2088–2093
37. Schroder PM, Khattar M, Deng R, Xie A, Chen W, Stepkowski SM (2013) Transient combination therapy targeting the immune synapse abrogates T cell responses and prolongs allograft survival in mice. PLoS One 8(7), e69397
38. Samelson LE (2002) Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol 20:371–394
39. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA (1997) Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 185:1413–1422
40. Madrenas J, Chau LA, Smith J, Bluestone JA, Germain RN (1997) The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/ partial agonist properties of peptide-MHC molecule ligands. J Exp Med 185:219–229
41. Chau LA, Bluestone JA, Madrenas J (1998) Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor. J Exp Med 187:1699–1709
42. Chau LA, Tso JY, Melrose J, Madrenas J (2001) HuM291(Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor. Transplantation 71:941–950
43. Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM (1994) Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 79:913–922
44. Combadiere B, Reis e Sousa C, Germain RN, Lenardo MJ (1998) Selective induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands. J Exp Med 187:349–355
45. Smith JA, Tang Q, Bluestone JA (1998) Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 160:4841–4849
46. Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA (2002) The Src family kinase Fyn mediates signals induced by TCR antagonists. J Immunol 168:4480–4487
47. Yu XZ, Zhu L, Davis JE, Tso JY, Hansen JA, Anasetti C (1996) Induction of apoptosis by anti-CD3 epsilon F(ab’)2 in antigen receptor transgenic murine T cells activated by specific peptide. J Immunol 157:3420–3429
48. Carpenter PA, Pavlovic S, Tso JY, Press OW, Gooley T, Yu XZ, Anasetti C (2000) Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol 165:6205–6213
49. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, Zheng L (1999) Mature T lymphocyte apoptosis—immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17:221–253
50. Sinclair C, Bains I, Yates AJ, Seddon B (2013) Asymmetric thymocyte death underlies the CD4:CD8 T-cell ratio in the adaptive immune system. PNAS 110(31):e2905–e2914